SCHEMBL17816138

SCHEMBL17816138

O=C(Nc1ccc(F)c(Cl)c1)c1ccc(I)c(SC2CCCCCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
NPSR1 Q6W5P4 1/20 0.48
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAOB P27338 4/20 0.45
MAPT P10636 2/20 0.45
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
KCNE1 P15382 1/20 0.45
KCNQ1 P51787 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
MAOA P21397 2/20 0.44
LMNA P02545 2/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17816113 0.92 NPC1 (0.47) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816127 0.92 NPC1 (0.47) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL19473172 0.91 NPC1 (0.54) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17784125 0.91 NPC1 (0.54) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816106 0.91 NPC1 (0.49) NPC1RAB9ANPSR1ALDH1A1MAOB
SCHEMBL17784101 0.90 NPC1 (0.53) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816104 0.90 NPC1 (0.47) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816185 0.90 NPC1 (0.46) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816092 0.90 NPSR1 (0.45) NPC1RAB9ANPSR1ALDH1A1SMN1; SMN2
SCHEMBL17816145 0.89 NPC1 (0.49) NPC1RAB9ANPSR1ALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016089990-A1 SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT NOVIRA THERAPEUTICS, INC. (US) 2016-06-09 WO disclosed